Dengue vaccines are designed to prevent dengue fever, a tropical illness spread by Aedes mosquitoes. The primary challenge in developing these vaccines lies in addressing the four different dengue virus serotypes (DENV-1, DENV-2, DENV-3, and DENV-4). Dengvaxia, approved in several countries, aims to protect against all four serotypes but has faced challenges due to varied effectiveness and safety concerns, particularly in individuals without prior dengue exposure. Newer developments also include innovative approaches like DNA vaccines and virus-like particle vaccines, which offer the potential for improved safety and broader immunity. As research progresses, these vaccines are anticipated to play a crucial role in controlling dengue fever, especially in endemic regions, by reducing disease incidence and preventing severe outcomes.
According to SPER Market Research, ‘Dengue Vaccines Market Size- By Type of Vaccine, By Vaccine Phase, By Distribution Channel - Regional outlook, Competitive Strategies and Segment Forecast to 2033’ States that the Global Dengue Vaccines Market is estimated to reach USD 1813.95 million by 2033 with a CAGR of 13.11 %.
Drivers:
One of the key variables driving the dengue immunization market development is the fast development in sickness pervasiveness. The variables adding to the ascent in dengue cases include an increment in populace thickness and an unnatural weather change. According to the NIH, 3.6 billion individuals who live in tropical and subtropical locales are in danger of dengue transmission. Worldwide assessments shift, however almost 0.05 to 0.2 billion instances of dengue diseases are accounted for yearly. According to the NIH, the upper bound absolute was 3.97 billion for individuals in danger of dengue in 128 nations all around the world. The genuine frequency instances of dengue are supposed to be essentially higher than the announced cases due to unfortunate sickness observation, symptomatic challenges, and fewer revealed dengue cases. The specific pervasiveness of dengue and its monetary impact is obscure. In excess of 125 nations are accepted all around the world be dengue-endemic.
Restraints:
The powerlessness to recognize dengue fever from other febrile sicknesses is supposed to thwart the development of the market. Such as the side effects of mosquito-borne illnesses like Zika, chikungunya infection disease, and dengue fever are practically the same, which makes the finding troublesome. Besides, an absence of comprehension of the pathophysiology of dengue disease and the absence of explicit creature models is supposed to prevent the development of the market. Public perception and vaccine hesitancy pose additional challenges, influenced by concerns over vaccine safety and efficacy. Lastly, the development of vaccines must contend with the logistics of mass vaccination in tropical and often resource-limited settings, where healthcare infrastructure may be underdeveloped. This issue is compounded by the need for large-scale vaccination campaigns and effective distribution networks.
Request For Free Sample Report @ https://www.sperresearch.com/report-store/dengue-vaccines-market.aspx?sample=1
The focus on COVID-19 diverted resources, funding, and research efforts away from other infectious diseases, including dengue. This shift has slowed progress in the development and approval of new dengue vaccines. The pandemic disrupted ongoing dengue vaccine clinical trials due to lockdowns, travel restrictions, and redeployment of clinical staff to COVID-19-related work. This has delayed the timelines for vaccine development and approval. COVID-19 overwhelmed healthcare systems globally, diverting attention and resources away from routine vaccination programs, including those for dengue. This strain has affected the ability to maintain or expand dengue vaccination programs in endemic regions. The pandemic has caused significant disruptions in global supply chains, impacting the production and distribution of vaccines, including those for dengue.
The Asia Pacific dominates the Global Dengue Vaccines Market due to it drives demand for vaccination programs, making the APAC region a focal point for dengue vaccine manufacturers. Major players in the market are Butantan Institute, GeneOne Life Science Inc., GlaxoSmithKline Plc, Mylan N.V., Medigen Vaccine Biologics Corporation.
Global Dengue Vaccines Market Segmentation:
By Type of Vaccine: Based on the Type of Vaccine, Global Dengue Vaccines Market is segmented as; Live Attenuated Vaccines, Recombinant Vaccines.
By Vaccine Phase: Based on the Vaccine Phase, Global Dengue Vaccines Market is segmented as; Phase I, Phase II, Phase III.
By Distribution Channel: Based on the Distribution Channel, Global Dengue Vaccines Market is segmented as; Hospitals, Clinics, Retail Pharmacies.
By Region: This research also includes data for North America, Asia-Pacific, Latin America, Middle East & Africa and Europe.
For More Information, refer to below link:-
Dengue Vaccines Market Outlook
Related Reports:
Contact Us:
Sara Lopes, Business Consultant – USA
SPER Market Research
+1-347-460-2899
